Sirolimus for epileptic seizures associated with focal cortical dysplasia type II.

Mitsuhiro KatoAkiko KadaHideaki ShiraishiJun TohyamaEiji NakagawaYukitoshi TakahashiTomoyuki AkiyamaAkiyoshi KakitaNoriko MiyakeAtsushi FujitaAkiko M SaitoYushi Inoue

Published in: Annals of clinical and translational neurology (2022)

The reduction of focal seizures did not meet the predetermined level of statistical significance. The safety profile of the drug was tolerable. The potential for a reduction of focal seizures over time merit further investigations.

Keyphrases

temporal lobe epilepsy
emergency department
risk assessment
human health
adverse drug
drug induced
electronic health record